Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2004

View Archived Issues

Enclomiphene increases testosterone in hypogonadal men

New photosensitizer isolated from plant extract by AIST scientists

Novel kappa opioid agonists developed at SSP

Roche researchers identify new uPA antagonists for use in cancer therapy

Merck scientists present new nonsteroidal glucocorticoid receptor modulators

Kyorin patent covers novel S1P receptor ligands and their use

New TARC and MDC regulators prepared and tested at Kyowa Hakko

Novel prostanoid DP antagonists under study at Taisho

Merck KGaA presents novel factor Xa and factor VIIa inhibitors

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: Neovacs

New phase III study for Ushercell in HIV

Positive findings from pharmacokinetic study of lingual spray sumatriptan

Oxytrol launched in Canada

Canadian warning on Eprex use in cancer patients

New safety information regarding Permax

ThromboView cleared to enter phase II study

ViRexx to acquire AltaRex Medical

Conversion of Sanctura agreement

Patient dosing begins for oral forodesine hydrochloride in phase I study

Restructuring at CuraGen

NDA submission for indiplon immediate release

STTR grant to fund development of SP-04 for Alzheimer's

ReGen to acquire Guildford Clinical Pharmacology Unit

Pharmacokinetics and safety profile of bazedoxifene in Chinese women

Paroxetine controlled release reported to be safe and effective in fibromyalgia

DailyDrugNews.com now featuring links to related information in Prous Science Integrity

LFM-A13 effective in model of graft-versus-host disease

Erectile dysfunction treatment with tadalafil extensively studied

IL-8 inhibition with statins a possible therapy for endometriosis

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026